19:20 , Oct 11, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma Patient sample and mouse studies suggest HAPLN1 could help treat metastatic melanoma. In 192 non-metastatic melanoma patients, high regional lymphatic tissue expression of HAPLN1 correlated with survival. In a mouse model of metastatic...
00:33 , Sep 28, 2018 |  BC Innovations  |  Targets & Mechanisms

Cell metabolism’s migration

As cancer metabolism undergoes a renaissance in the clinic, with compounds targeting growth factor and nutrient sensing pathways, basic research on metabolic processes in all cells is shining light on pathways that could yield new...
00:46 , Aug 4, 2018 |  BioCentury  |  Finance

Functions of formulation

Halozyme Therapeutics Inc. is quickly expanding the reach of its Enhanze platform on the back of regulatory approvals for products that are now gaining market share, plus a playbook for streamlined early development it can...
19:59 , Jan 19, 2018 |  BC Week In Review  |  Clinical News

Halozyme's PEGPH20 leads to worse OS in first-line pancreatic cancer

Halozyme Therapeutics Inc. (NASDAQ:HALO) reported that PEGPH20 plus modified FOLFIRINOX chemotherapy led to worse overall survival (OS) compared with chemotherapy alone in the Phase Ib/II S1313 trial to treat previously untreated metastatic pancreatic cancer. The...
20:05 , Jan 17, 2018 |  BC Extra  |  Clinical News

First-line pancreatic cancer readout sinks Halozyme shares

Halozyme Therapeutics Inc. (NASDAQ:HALO) slipped $1.76 to $17.98 Wednesday after reporting that PEGPH20 plus modified FOLFIRINOX chemotherapy led to worse overall survival (OS) compared with chemotherapy alone in the Phase Ib/II S1313 trial to treat...
00:18 , Dec 22, 2017 |  BC Week In Review  |  Company News

Alexion licenses Halozyme's drug delivery tech

Halozyme Therapeutics Inc. (NASDAQ:HALO) granted Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) a license to use its Enhanze technology to develop subcutaneous formulations of therapies against up to four targets, including a new formulation of ALXN1210. Halozyme will...
19:04 , Dec 8, 2017 |  BC Week In Review  |  Clinical News

Halozyme starts Phase Ib/II of PEGPH20 plus Tecentriq

In October, Halozyme Therapeutics Inc. (NASDAQ:HALO) began the Phase Ib/II HALO-110-101 trial to evaluate PEGPH20 in combination with standard chemotherapy with or without Tecentriq atezolizumab to treat previously untreated, unresectable, locally advanced, or metastatic cholangiocarcinoma...
19:37 , Oct 6, 2017 |  BC Week In Review  |  Clinical News

BioTime reports additional data for Renevia facial lipoatrophy device

BioTime Inc. (NYSE-M:BTX; Tel Aviv:BTX) reported long-term data from a European pivotal trial of Renevia to treat HIV-associated lipoatrophy, which the company said is a severe form of lipoatrophy characterized by the pathological loss of...
21:09 , Sep 15, 2017 |  BC Week In Review  |  Company News

Halozyme increases revenue guidance on BMS, Roche deals

Halozyme Therapeutics Inc. (NASDAQ:HALO) raised its 2017 revenue guidance after announcing two separate licensing deals for its Enhanze drug-delivery technology with Bristol-Myers Squibb Co. (NYSE:BMY) and Roche (SIX:ROG; OTCQX:RHHBY). The biotech now expects 2017 revenues...
22:21 , Sep 14, 2017 |  BC Extra  |  Company News

Halozyme increases revenue guidance on BMS, Roche deals

Halozyme Therapeutics Inc. (NASDAQ:HALO) jumped $2.80 (21%) to $15.98 and raised its 2017 revenue guidance on Thursday after announcing two separate licensing deals for its Enhanze drug-delivery technology with Bristol-Myers Squibb Co. (NYSE:BMY) and Roche...